185 related articles for article (PubMed ID: 29286561)
21. DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling.
Kim SS; Kycia I; Karski M; Ma RK; Bordt EA; Kwan J; Karki A; Winter E; Aktas RG; Wu Y; Emili A; Bauer DE; Sethupathy P; Vakili K
PLoS One; 2022; 17(2):e0263829. PubMed ID: 35167623
[TBL] [Abstract][Full Text] [Related]
22. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma.
Graham RP; Yeh MM; Lam-Himlin D; Roberts LR; Terracciano L; Cruise MW; Greipp PT; Zreik RT; Jain D; Zaid N; Salaria SN; Jin L; Wang X; Rustin JG; Kerr SE; Sukov WR; Solomon DA; Kakar S; Waterhouse E; Gill RM; Ferrell L; Alves VA; Nart D; Yilmaz F; Roessler S; Longerich T; Schirmacher P; Torbenson MS
Mod Pathol; 2018 Jan; 31(1):141-149. PubMed ID: 28862261
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma.
Dinh TA; Jewell ML; Kanke M; Francisco A; Sritharan R; Turnham RE; Lee S; Kastenhuber ER; Wauthier E; Guy CD; Yeung RS; Lowe SW; Reid LM; Scott JD; Diehl AM; Sethupathy P
Cell Mol Gastroenterol Hepatol; 2019; 7(4):803-817. PubMed ID: 30763770
[TBL] [Abstract][Full Text] [Related]
24. Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells.
Oikawa T; Wauthier E; Dinh TA; Selitsky SR; Reyna-Neyra A; Carpino G; Levine R; Cardinale V; Klimstra D; Gaudio E; Alvaro D; Carrasco N; Sethupathy P; Reid LM
Nat Commun; 2015 Oct; 6():8070. PubMed ID: 26437858
[TBL] [Abstract][Full Text] [Related]
25. Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.
Lalazar G; Simon SM
Semin Liver Dis; 2018 Feb; 38(1):51-59. PubMed ID: 29471565
[TBL] [Abstract][Full Text] [Related]
26. Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma.
Riggle KM; Riehle KJ; Kenerson HL; Turnham R; Homma MK; Kazami M; Samelson B; Bauer R; McKnight GS; Scott JD; Yeung RS
Pediatr Res; 2016 Jul; 80(1):110-8. PubMed ID: 27027723
[TBL] [Abstract][Full Text] [Related]
27. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
[TBL] [Abstract][Full Text] [Related]
28. The Use of Fluorescence
Weiel JJ; Forgo B; Sage J; Rangaswami A; Hazard FK
Ann Clin Lab Sci; 2022 May; 52(3):475-483. PubMed ID: 35777788
[TBL] [Abstract][Full Text] [Related]
29. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.
Simon EP; Freije CA; Farber BA; Lalazar G; Darcy DG; Honeyman JN; Chiaroni-Clarke R; Dill BD; Molina H; Bhanot UK; La Quaglia MP; Rosenberg BR; Simon SM
Proc Natl Acad Sci U S A; 2015 Nov; 112(44):E5916-25. PubMed ID: 26489647
[TBL] [Abstract][Full Text] [Related]
30. Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.
Graham RP; Terracciano LM; Meves A; Vanderboom PM; Dasari S; Yeh MM; Torbenson MS; Cruise MW
Mod Pathol; 2016 Jun; 29(6):607-15. PubMed ID: 27015136
[TBL] [Abstract][Full Text] [Related]
31. FGFR1 and FGFR2 in fibrolamellar carcinoma.
Graham RP; Garcia JJ; Greipp PT; Barr Fritcher EG; Kipp BR; Torbenson MS
Histopathology; 2016 Apr; 68(5):686-92. PubMed ID: 26259677
[TBL] [Abstract][Full Text] [Related]
32. DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.
Kirk AM; Crawford JC; Chou CH; Guy C; Pandey K; Kozlik T; Shah RK; Chung S; Nguyen P; Zhang X; Wang J; Bell M; Mettelman RC; Allen EK; Pogorelyy MV; Kim H; Minervina AA; Awad W; Bajracharya R; White T; Long D; Gordon B; Morrison M; Glazer ES; Murphy AJ; Jiang Y; Fitzpatrick EA; Yarchoan M; Sethupathy P; Croft NP; Purcell AW; Federico SM; Stewart E; Gottschalk S; Zamora AE; DeRenzo C; Strome SE; Thomas PG
Cell Rep Med; 2024 Mar; 5(3):101469. PubMed ID: 38508137
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the chimeric DnaJ-PKAc enzyme by endogenous inhibitor proteins.
Averill AM; Rehman HT; Charles JW; Dinh TA; Danyal K; Verschraegen CF; Stein GS; Dostmann WR; Ramsey JE
J Cell Biochem; 2019 Aug; 120(8):13783-13791. PubMed ID: 30938854
[TBL] [Abstract][Full Text] [Related]
34. Genomic analysis of fibrolamellar hepatocellular carcinoma.
Xu L; Hazard FK; Zmoos AF; Jahchan N; Chaib H; Garfin PM; Rangaswami A; Snyder MP; Sage J
Hum Mol Genet; 2015 Jan; 24(1):50-63. PubMed ID: 25122662
[TBL] [Abstract][Full Text] [Related]
35. Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings.
Graham RP; Torbenson MS
Semin Diagn Pathol; 2017 Mar; 34(2):146-152. PubMed ID: 28110996
[TBL] [Abstract][Full Text] [Related]
36. Management of fibrolamellar hepatocellular carcinoma.
Chaudhari VA; Khobragade K; Bhandare M; Shrikhande SV
Chin Clin Oncol; 2018 Oct; 7(5):51. PubMed ID: 30395718
[TBL] [Abstract][Full Text] [Related]
37. Defective internal allosteric network imparts dysfunctional ATP/substrate-binding cooperativity in oncogenic chimera of protein kinase A.
Olivieri C; Walker C; Karamafrooz A; Wang Y; Manu VS; Porcelli F; Blumenthal DK; Thomas DD; Bernlohr DA; Simon SM; Taylor SS; Veglia G
Commun Biol; 2021 Mar; 4(1):321. PubMed ID: 33692454
[TBL] [Abstract][Full Text] [Related]
38. A framework for fibrolamellar carcinoma research and clinical trials.
Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P
Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728
[TBL] [Abstract][Full Text] [Related]
39. Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases.
Ganeshan D; Szklaruk J; Kaseb A; Kattan A; Elsayes KM
Abdom Radiol (NY); 2018 Dec; 43(12):3340-3348. PubMed ID: 29948061
[TBL] [Abstract][Full Text] [Related]
40. Environmental exposures as a risk factor for fibrolamellar carcinoma.
Graham RP; Craig JR; Jin L; Oliveira AM; Bergquist JR; Truty MJ; Mounajjed T; Greipp PT; Torbenson MS
Mod Pathol; 2017 Jun; 30(6):892-896. PubMed ID: 28256571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
